News & Updates

Antihypertensive dosing TIME does not affect CV outcomes
Antihypertensive dosing TIME does not affect CV outcomes
26 Sep 2022 byRoshini Claire Anthony

Timing of antihypertensive medication intake, be it in the morning or evening, does not appear to affect the risk of cardiovascular death or hospitalization for non-fatal myocardial infarction (MI) or non-fatal stroke, according to results of the TIME trial presented at ESC 2022.

Antihypertensive dosing TIME does not affect CV outcomes
26 Sep 2022
Does frozen embryo transfer up hypertension risk during pregnancy?
Does frozen embryo transfer up hypertension risk during pregnancy?
25 Sep 2022 byRoshini Claire Anthony

The risk of hypertensive disorders in pregnancy (HDP) is increased following assisted reproductive technology (ART) using frozen embryo transfer (FET) compared with after fresh embryo transfer or natural conception, according to results of a study presented at ESHRE 2022.

Does frozen embryo transfer up hypertension risk during pregnancy?
25 Sep 2022
DANFLU-1: High-dose quadrivalent flu vax reduces hospitalization, death in older adults
DANFLU-1: High-dose quadrivalent flu vax reduces hospitalization, death in older adults
22 Sep 2022 byRoshini Claire Anthony

Older adults who receive a high-dose quadrivalent influenza vaccine have a 49 percent reduced risk of death and a 64 percent reduced risk of hospitalization for influenza or pneumonia compared with those who receive a standard-dose vaccine, results of the DANFLU-1 study showed.

DANFLU-1: High-dose quadrivalent flu vax reduces hospitalization, death in older adults
22 Sep 2022
PDE5-I use poses no excess cardiovascular, mortality risk in diabetic men with ED
PDE5-I use poses no excess cardiovascular, mortality risk in diabetic men with ED
20 Sep 2022

The presence of erectile dysfunction (ED) does not appear to confer an increased risk of cardiovascular disease (CVD) and mortality in men with diabetes mellitus (DM), with comparable risk of adverse cardiovascular events among users and nonusers of phosphodiesterase-5 inhibitors (PDE5-Is), which are used to manage ED, according to a study.

PDE5-I use poses no excess cardiovascular, mortality risk in diabetic men with ED
20 Sep 2022